Home treatment in paediatric patients with Hunter syndrome: The first Italian experience

Italian Journal of Pediatrics

Volumn 39, Issue 1, 2013, Pages

  Ceravolo, Ferdinando ^a,b   Mascaro, Italia ^a   Sestito, Simona ^a   Pascale, Elisa ^a   Lauricella, Antonino ^a   Dizione, Elio ^a   Concolino, Daniela ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Enzyme replacement therapy; Home treatment (max 6); Hunter syndrome; Idursulfase; Mucopolysaccharidoses

Indexed keywords

IDURONATE 2 SULFATASE;

ADOLESCENT; ARTICLE; CASE REPORT; CHILD; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ENZYME ISOLATION; ENZYME REPLACEMENT; HOME CARE; HUMAN; HUNTER SYNDROME; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; QUALITY OF LIFE; SCHOOL CHILD; SCORING SYSTEM; TREATMENT DURATION;

ADOLESCENT; CHILD; COHORT STUDIES; COST SAVINGS; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; FEMALE; HOME INFUSION THERAPY; HUMANS; IDURONATE SULFATASE; INFUSIONS, INTRAVENOUS; ITALY; MALE; MUCOPOLYSACCHARIDOSIS II; PATIENT SAFETY; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 84884562503     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/1824-7288-39-53     Document Type: Article

References (9)

1. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V, Muenzer J, Pediatrics 2008 121 377 e386 10.1542/peds.2007-1350 18245410 (Pubitemid 351198459)
2. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga AC, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A, Genet Med 2006 8 465 473 10.1097/01.gim.0000232477.37660.fb 16912578
3. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, et al. Orphanet J Rare Dis 2011 6 72 10.1186/1750-1172-6-72 22059643
4. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. Bagewadi S, Roberts J, Mercer J, Jones S, Stephenson J, Wraith JE, J Inherit Metab Dis 2008 31 733 737 10.1007/s10545-008-0980-0 18923918
5. Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses. Burton BK, Wiesman C, Paras A, Kim K, Katz R, Mol Genet Metab 2009 97 234 236 10.1016/j.ymgme.2009.04.007 19427803
6. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II-data from the Hunter Outcome Survey. Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA, Mol Genet Metab 2010 101 123 129 10.1016/j.ymgme.2010.06.011 20638311
7. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe. Cox-Brinkman J, Timmermans RG, Wijburg FA, Donker WE, van de Ploeg AT, Aerts JM, Hollak CE, J Inherit Metab Dis 2007 30 984 10.1007/s10545-007-0686-8 17879143
8. Measurement of quality of life using EQ-5D in patients on prolonged mechanical ventilation: comparison of patients, family caregivers, and nurses. Hung MC, Yan YH, Fan PS, Lin MS, Chen CR, Kuo LC, Yu CJ, Yao G, Hsieh CL, Wang JD, Qual Life Res 2010 19 721 727 10.1007/s11136-010-9629-1 20224902
9. Psychometric properties of the EQ-5D in a study of people with mild to moderate dementia. Kunz S, Qual Life Res 2010 19 425 434 10.1007/s11136-010- 9600-1 20146008